ZNF683

Across TCGA pan-cancer cohorts, ZNF683 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZNF683 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ZNF683 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF683 expression acts as an unfavorable survival marker.

GBM, LUSC, and CESC are the cancer types where ZNF683 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.062	0.258	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.002	0.733	<.001	12	view →
CESC	OS	Median	IV	0.095	0.592	.004	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	II,III,IV	0.143	0.687	.003	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	OS	Median	All	0.142	0.545	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZNF683–GBM (DFS)

Open the GBM breakdown →